Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.98 USD | -0.60% | -2.93% | +19.20% |
Dec. 06 | Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays | CI |
Nov. 09 | Needham Adjusts Price Target on OncoCyte to $3.60 From $4.25, Maintains Buy Rating | MT |
Evolution of the average Target Price on OncoCyte Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering OncoCyte Corporation
Needham & Co. | |
Benchmark Company | |
Piper Sandler | |
Lake Street | |
Stephens Inc. | |
KeyBanc Capital Markets | |
Chardan |
EPS Revisions
- Stock
- Equities
- Stock OncoCyte Corporation - Nasdaq
- Consensus OncoCyte Corporation